Metformin Improves Glucose Effectiveness, Not Insulin Sensitivity: Predicting Treatment Response in Women With Polycystic Ovary Syndrome in an Open-Label, Interventional Study
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Context: Although metformin is widely used to improve insulin resistance in women with polycystic ovary syndrome (PCOS), its mechanism of action is complex, with inconsistent effects on insulin sensitivity and variability in treatment response. Objective: The aim of the study was to delineate the effect of metformin on glucose and insulin parameters, determine additional treatment outcomes, and predict patients with PCOS who will respond to treatment. Design and Setting: We conducted an open-label, interventional study at an academic medical center. Subjects: Women with PCOS (n = 36) diagnosed by the National Institutes of Health criteria participated in the study. Interventions: Subjects underwent fasting blood sampling, an IV glucose tolerance test, dual-energy x-ray absorptiometry scan, transvaginal ultrasound, and measurement of human chorionic gonadotropin-stimulated androgen levels before and after 12 weeks of treatment with metformin extended release 1500 mg/d. Interval visits were performed to monitor anthropometric measurements and menstrual cycle parameters. Main Outcome Measures: Changes in glucose and insulin parameters, androgen levels, anthropometric measurements, and ovulatory menstrual cycles were evaluated. Results: Insulin sensitivity did not change despite weight loss. Glucose effectiveness (P = .002) and the acute insulin response to glucose (P = .002) increased, and basal glucose levels (P = .001) decreased after metformin treatment. T levels also decreased. Women with improved ovulatory function (61%) had lower baseline T levels and lower baseline and stimulated T and androstenedione levels after metformin treatment (all P < .05). Conclusions: Using an IV glucose tolerance test, which distinguishes improvements in glucose effectiveness and insulin sensitivity, metformin does not improve insulin sensitivity in women with PCOS but does improve glucose effectiveness. The improvement in glucose effectiveness may be partially mediated by decreased glucose levels. T levels also decreased with metformin treatment. Ovulation during metformin treatment was associated with lower baseline T levels and greater T and androstenedione decreases during treatment, but not with insulin or LH levels. Thus, the action of metformin in PCOS primarily affects glucose levels and steroidogenesis, which may be mediated by mechanisms that affect both pathways, such as inhibition of mitochondrial complex I.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Franks, S. (1995) · New England Journal of Medicine · doi:10.1056/nejm199509283331307 · Cited by 2,463
OWEN, M. R., DORAN, E., & HALESTRAP, A. P. (2000) · Biochemical Journal · doi:10.1042/bj3480607 · Cited by 2,157
Profound Peripheral Insulin Resistance, Independent of Obesity, in Polycystic Ovary Syndrome
Dunaif, A., Segal, K. R., Futterweit, W., & Dobrjansky, A. (1989) · Diabetes · doi:10.2337/diab.38.9.1165 · Cited by 1,967
Legro, R. S. (1999) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.1.165 · Cited by 1,743
El-Mir, M.-Y., Nogueira, V., Fontaine, E., Avéret, N., Rigoulet, M., & Leverve, X. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.1.223 · Cited by 1,399
Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome.
Ehrmann, D. A., Barnes, R. B., Rosenfield, R. L., Cavaghan, M. K., & Imperial, J. (1999) · Diabetes Care · doi:10.2337/diacare.22.1.141 · Cited by 1,257
Foretz, M., Hébrard, S., Leclerc, J., Zarrinpashneh, E., Soty, M., Mithieux, G., Sakamoto, K., Andreelli, F., & Viollet, B. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40671 · Cited by 1,181
Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome
Legro, R. S., Barnhart, H. X., Schlaff, W. D., Carr, B. R., Diamond, M. P., Carson, S. A., Steinkampf, M. P., Coutifaris, C., McGovern, P. G., Cataldo, N. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa063971 · Cited by 1,027
Toward Physiological Understanding of Glucose Tolerance: Minimal-Model Approach
Bergman, R. N. (1989) · Diabetes · doi:10.2337/diab.38.12.1512 · Cited by 1,001
Prevalence and Characteristics of the Metabolic Syndrome in Women with Polycystic Ovary Syndrome
Apridonidze, T., Essah, P. A., Iuorno, M. J., & Nestler, J. E. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1045 · Cited by 931
Musi, N., Hirshman, M. F., Nygren, J., Svanfeldt, M., Bavenholm, P., Rooyackers, O., Zhou, G., Williamson, J. M., Ljunqvist, O., Efendic, S., et al. (2002) · Diabetes · doi:10.2337/diabetes.51.7.2074 · Cited by 806
Nestler, J. E., & Jakubowicz, D. J. (1996) · New England Journal of Medicine · doi:10.1056/nejm199608293350902 · Cited by 743
Insulin resistance in nonobese patients with polycystic ovarian disease
CHANG, R. J., NAKAMURA, R. M., JUDD, H. L., & KAPLAN, S. A. (1983) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-57-2-356 · Cited by 704
Prevalence and Predictors of the Metabolic Syndrome in Women with Polycystic Ovary Syndrome
Ehrmann, D. A., Liljenquist, D. R., Kasza, K., Azziz, R., Legro, R. S., & Ghazzi, M. N. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1329 · Cited by 703
Tang, T., Lord, J. M., Norman, R. J., Yasmin, E., & Balen, A. H. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003053.pub5 · Cited by 698
Pacini, G., & Bergman, R. N. (1986) · Computer Methods and Programs in Biomedicine · doi:10.1016/0169-2607(86)90106-9 · Cited by 695
Moghetti, P., Castello, R., Negri, C., Tosi, F., Perrone, F., Caputo, M., Zanolin, E., & Muggeo, M. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.1.6293 · Cited by 660
Ehrmann, D. A., Sturis, J., Byrne, M. M., Karrison, T., Rosenfield, R. L., & Polonsky, K. S. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118064 · Cited by 426
Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects
DEFRONZO, R. A., BARZILAI, N., & SIMONSON, D. C. (1991) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-73-6-1294 · Cited by 408
Baillargeon, J.-P., Jakubowicz, D. J., Iuorno, M. J., Jakubowicz, S., & Nestler, J. E. (2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2004.02.127 · Cited by 300
Azziz, R., Hincapie, L. A., Knochenhauer, E. S., Dewailly, D., Fox, L., & Boots, L. R. (1999) · Fertility and Sterility · doi:10.1016/s0015-0282(99)00383-0 · Cited by 244
Insulin sensitizers may attenuate lean mass loss in older men with diabetes
Lee, C. G., Boyko, E. J., Barrett-Connor, E., Miljkovic, I., Hoffman, A. R., Everson-Rose, S. A., Lewis, C. E., Cawthon, P. M., Strotmeyer, E. S., Orwoll, E. S., et al. (2011) · Diabetes Care · doi:10.2337/dc11-1032 · Cited by 168
Hirsch, A., Hahn, D., Kempná, P., Hofer, G., Nuoffer, J.-M., Mullis, P. E., & Flück, C. E. (2012) · Endocrinology · doi:10.1210/en.2012-1145 · Cited by 109
Cited by
Rosenfield, R. L., & Ehrmann, D. A. (2016) · Endocrine Reviews · doi:10.1210/er.2015-1104 · Cited by 1,603
Poly Cystic Ovarian Syndrome: An Updated Overview
El Hayek, S., Bitar, L., Hamdar, L. H., Mirza, F. G., & Daoud, G. (2016) · Frontiers in Physiology · doi:10.3389/fphys.2016.00124 · Cited by 323
Effects of metformin on weight loss: potential mechanisms
Malin, S. K., & Kashyap, S. R. (2014) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000095 · Cited by 223
“Nonetheless, recent work indicates that metformin at lower doses of 1000–1500 mg/day is a viable antiobesity agent in individuals with psychiatric disorders [12] and polycystic ovarian syndrome [13] that are associated with insulin resistance and weight gain, supporting the notion that metformin is a credible weight l…”
BackgroundMetformin therapy for the reproductive and metabolic consequences of polycystic ovary syndrome
Sam, S., & Ehrmann, D. A. (2017) · Diabetologia · doi:10.1007/s00125-017-4306-3 · Cited by 93
Metformin: an old therapy that deserves a new indication for the treatment of obesity.
Igel, L. I., Sinha, A., Saunders, K. H., Apovian, C. M., Vojta, D., & Aronne, L. J. (2016) · Current Atherosclerosis Reports · doi:10.1007/s11883-016-0568-3 · Cited by 52
Metadata
- Authors
- Pau, C. T., Keefe, C., Duran, J., & Welt, C. K.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2014-05-01
- Volume
- 99
- Issue
- 5
- Pages
- 1870-1878
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2106671270
- Cited by
- 49
- References
- 23
- FWCI
- 7.18
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.